Brief: Prelude Therapeutics Announces Fourth Quarter And Full Year 2020 Financial Results And Provides Operational Update
16/03/2021 13:08
March 16 (Reuters) - Prelude Therapeutics Inc PRLD.O :
* PRELUDE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL
YEAR 2020
FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE
* Q4 LOSS PER SHARE $0.45
* Q4 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES
DATA
* CURRENT CASH & CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND
OPERATING EXPENSES & CAPITAL EXPENDITURE REQUIREMENTS INTO 2023
Source text for Eikon: ID:nGNX6BZGwR
Further company coverage: PRLD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview